Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma Plc LSE:MTPH London Ordinary Share GB00BKT14T00 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  1.75 6.86% 27.25 1,594,703 16:06:31
Bid Price Offer Price High Price Low Price Open Price
27.00 27.50 28.50 25.50 25.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.31 -10.92 -50.00 27
Last Trade Time Trade Type Trade Size Trade Price Currency
16:17:21 O 2,500 27.00 GBX

Midatech Pharma (MTPH) Latest News (6)

More Midatech Pharma News
Midatech Pharma Investors    Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date Time Title Posts
17/9/202113:36Midatech Pharma (MTPH) sees 10-fold increase1,858
24/1/202119:14Midatech Pharma 4
21/7/202012:16 Midatech Pharma Plc9
30/4/201921:51Midatech Pharma (MTPH) One to Watch 2
03/1/201712:41Midatech Pharma PLC181

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-09-17 15:17:2227.002,500675.00O
2021-09-17 15:11:2527.0015,0004,050.00O
2021-09-17 15:06:3227.50400110.00O
2021-09-17 15:04:0527.2615,0004,089.00O
2021-09-17 14:57:4727.454,6161,267.09O
View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

Midatech Pharma Daily Update: Midatech Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 25.50p.
Midatech Pharma Plc has a 4 week average price of 24.75p and a 12 week average price of 24.75p.
The 1 year high share price is 50.50p while the 1 year low share price is currently 23p.
There are currently 98,468,387 shares in issue and the average daily traded volume is 170,753 shares. The market capitalisation of Midatech Pharma Plc is £26,832,635.46.
wapper: Hi Babbler. I do seem to recall that this share does spike 2 or 3 times a year quite spectacularly .
babbler: Wait for presentation Monday. But if you expected a huge spike to sell into this isn't the share for you.
david gruen: Midatech Pharma PLC 17 September 2021 17 September 2021 Midatech Pharma Plc Interim results for the six months ended 30 June 2021 Midatech Pharma PLC (AIM: MTPH.L; NASDAQ: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its unaudited interim results for the six months ended 30 June 2021. OPERATIONAL HIGHLIGHTS On 17 June 2021, the Company announced significant progress across a number of R&D programmes including: Q-Sphera -- Breakthrough data on the successful encapsulation of an exemplar monoclonal antibody (mAb); -- The delivery of proof of concept formulations of MTX214 and MTX216 to the Company's collaboration partner for the partner's in vivo studies; and -- The successful development of MTD211, a long-acting formulation of brexpiprazole which, in in vivo studies, demonstrated therapeutic blood levels over a period of three months. MTX110 -- Demonstration, in vitro, of the potency of MTX110 in four patient-derived Glioblastoma cell lines. FINANCIAL HIGHLIGHTS (including post period end) -- Total revenue in H1 2021 was GBP0.40m (1H20: GBP0.17m). Total revenue represents income from R&D collaborations plus grant revenue. -- Research and development costs decreased by 50% to GBP2.01m (1H20: GBP3.99m) as a result of the termination of MTD201 and focus on multiple earlier stage programmes. -- Administrative expenses decreased 44% to GBP1.64m (1H20: GBP2.93m) due to expenses incurred in connection with the Strategic Review and restructuring in the prior period. -- Net cash used in operating activities (after changes in working capital) in 1H21 was GBP3.11m, compared with GBP7.09m in 1H20. -- In July, post period end, the Company raised GBP10.0m before expenses in an UK Placing of 35.1m ordinary shares at GBP0.285 per share. -- The cash balance on 30 June 2021 was GBP4.20m. . Commenting, Stephen Stamp, CEO and CFO of Midatech said : "We are pleased to report good progress throughout the Company and an expanded and exciting pipeline of programmes and opportunities. The disruption and costs of the restructuring in 2020 are now behind us. The first half of 2021 has been highly productive with three potentially viable Q-Sphera formulations, one internal and two for a collaboration partner. We believe the breakthrough data on the encapsulation of a protein could prove to be a very significant opportunity for Midatech." The Company will be hosting a webinar at 5.30pm BST / 12.30pm EST on Monday 20 September 2021. The webinar is open to all existing and potential shareholders and those interested in attending may register via the following link where, following registration, they will be provided with access details: hxxps://us02web.zoom.us/webinar/register/WN_vLpYaALlRYqUXveBsffy7w
kingston78: I note that the share price has stabilised at around 25-26 p and it is actually below the recent placing price. I suspect that a reasonably encouraging news will propel the share price upwards through the 30 p barrier, leading to 40 p.
kingston78: This board has gone quiet. Does anyone have any news on the company's business development? Its share price is not going anywhere at present and I wonder why.
daniel: Well, It's important for the Directors to be aware that they have issued 40% of the company's shares capital in the past 1 month. While the award to Dmitry is acceptable, I don't feel the same about Stephen's exercise price of 27.75 pence per share. The share price has fallen too far, and shareholders are in massive losses without recourse to share options. The Board needs to realize that the company is grossly undervalued, and they need to fast-track commercialization and bring in new investors into the company. Thank you.
daniel: Midatech Pharma PLC ("Midatech" or the "Company") UK Placing to Raise GBP10.0 million Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has raised GBP10.0 million (before expenses) by way of a placing to investors in the UK ("Placing") of 35,087,720 new ordinary shares of 0.1p each ("Placing Shares") at an issue price of GBP0.285 per Placing Share ("Issue Price"). The Placing brings new UK institutions into the Company's shareholder base. Turner Pope Investments (TPI) Limited ("Turner Pope") acted as sole bookrunner for the Placing. Turner Pope participated in the Placing. The Issue Price of the Placing Shares represents a discount of approximately 12.3% to the closing middle market price of GBP0.325 per existing ordinary share on 28 June 2021, being the last business day before this announcement. The Placing Shares represent approximately 35.6% of the issued share capital of the Company as enlarged by the Placing. The allotment of the Placing Shares is being made pursuant to existing authorities to allot shares and other relevant securities and to disapply pre-emption rights under section 551 of the Companies Act 2006, which the Directors were given at the Company's General Meeting held on 2 March 2020. Background to the Placing On 17 June 2021, the Company announced a series of updates to its R&D programmes including: -- data that demonstrate the Company has been able to encapsulate an exemplar monoclonal antibody ("mAb") using its Q-Sphera technology while preserving its functional integrity and antigen binding; -- delivery of proof of concept Q-Sphera formulations of MTX214 and MTX216 for the Company's collaboration partner to initiate in vivo IND-enabling studies; -- in vivo data to support a three month dosing interval for MTD211, the Company's formulation of long-acting brexpiprazole; -- start up activities for a Phase II study of MTX110 in Diffuse Intrinsic Pontine Glioma ("DIPG") following a positive pre-IND meeting with the FDA; and -- planning for a Phase I pilot study of MTX110 in Glioblastoma Multiforme ("GBM") following encouraging preclinical data which demonstrate the potency of MTX110 in multiple patient-derived GBM cell lines. Use of Proceeds The proceeds of the Placing, net of fees and expenses, are expected to be approximately GBP9.0 million ("Net Proceeds"). We expect the Net Proceeds will be used to: -- develop, to proof of concept stage, additional mAb formulations using the Company's Q-Sphera technology following the success with the exemplar mAb disclosed as part of the Company's R&D update on 17 June 2021; -- add new small molecule Q-Sphera programmes to the Company's internal pipeline; -- initiate a Phase II clinical study of MTX110 in DIPG; -- initiate a pilot Phase I clinical study of MTX110 in GBM; and -- general corporate purposes. Taking into account available cash resources and the expected Net Proceeds, the Company expects to have sufficient cash resources to fund operations into the first quarter of 2023. Further Information on the Placing The Company and Turner Pope entered into a placing agreement ("Placing Agreement"), pursuant to which Turner Pope agreed to use its reasonable endeavours to procure placees pursuant to the Placing. The Placing is not underwritten. Turner Pope has received binding commitments from placees to acquire the Placing Shares at the Issue Price. The Placing Agreement contains certain warranties and indemnities by the Company in favour of Turner Pope. It also contains provisions entitling Turner Pope to terminate the Placing Agreement prior to Admission, as defined below, if, among other things, a breach of any of the warranties occurs or on the occurrence of an event fundamentally and adversely affecting the position of the Company. The Placing is conditional upon, inter alia: (a) the Placing Agreement becoming unconditional in all respects (save for Admission occurring) and not having been terminated in accordance with its terms; and (b) Admission becoming effective by no later than 8.00 a.m. on 6 July 2021 (or such later time and/or date as the Company and Turner Pope may agree (being not later than 4.30 p.m. on 3 August 2021). Application for Admission to trading on AIM Subject to all conditions being met, application will be made for the 35,087,720 Placing Shares to be admitted to trading on AIM ("Admission"). It is expected that settlement of the Placing Shares and Admission will take place at 8.00 a.m. on or about 6 July 2021 and that dealings in the Placing Shares will commence at that time. When issued, the Placing Shares will be fully paid and will rank pari passu in all respects with the existing ordinary shares. Total Voting Rights Upon Admission, the Company's issued share capital will comprise 98,468,387 ordinary shares of 0.1p each with voting rights. The Company does not hold any shares in treasury. Upon Admission this figure of 98,468,387 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules. Commenting, Stephen Stamp, Midatech CEO and CFO, said: "It has been a busy 13 months since we announced our Strategic Review and restructuring. On 17 June 2021 we announced progress in our R&D pipeline across multiple programmes and breakthrough data on the successful encapsulation of a large molecule protein with Q-Sphera - a world's first. Today's announcement of the Placing gives us the runway to initiate Phase II and Phase I clinical studies of MTX110 in DIPG and GBM, respectively. Our focus now turns to lining up partners for these programmes." This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR). The person responsible for arranging the release of this announcement on behalf of the Company is Stephen Stamp, Chief Executive Officer and Chief Financial Officer. For more information, please contact: Midatech Pharma PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 2048 0180 www.midatechpharma.com
zb27: Ha manipulation of the highest order. A UT @ 31p for 58 shares! I think it will sort itself out in the morning. Official close was 35, with a spread of 34-36. It could still be the highest riser lol its so difficult to buy, i reckon this will shoot up very quickly, people will be wondering 'low 30s' jeez what a gift that was!common sense really went up 80% + on compang changing news, then baxk to where it was BEFORE the news came out. Makes no sense. Hopefully finds its real intrinsic value over the coming days/weeks. Next news, will put a rocket launcher up the share price. Should be trading in the ££, the market opportunity is out of this world!
zb27: Risk/Reward here is out of this world!Even a market cap of only £630m, share price would be £10!!! Low free float, always NT to buy, and todays game changing transformative news, would not be surprised if this starts to fly!! Could be ££ in not time.
mubz: https://www.marketscreener.com/MIDATECH-PHARMA-PLC-19157045/news/Midatech-Pharma-Letter-to-Deyan-Spiridonov-re-Midatech-30744197/ What is interesting is that this chap at Paul Hasting law firm- Deyan P. Spiridonov is a member of the firm's Mergers & Acquisitions practice. So have Secura Bio done this in order to trash MTPH share price and then put in a hostile bid to takeover Please be advised that in the event that Secura Bio refuses to withdraw its purported termination notice, Midatech and Midatech Limited will vigorously pursue any and all available remedies, including claims for monetary damages based on Secura Bio's intentional wrongdoing. Midatech and Midatech Limited also reserve all rights in law and equity against Secura Bio and its agents, including, without limitation, the right to pursue tort claims (and a recovery of fees and costs in the UK) resulting from Secura Bio's intentional efforts to cause harm to and to adversely affect Midatech's market position.
Midatech Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Midatech P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210918 07:15:53